Welcome to the ATECT Research Consortium

ATECT stands for "Advanced T-cell Engineering for Cancer Therapy".

We are an EU framework 7 funded consortium whose aims are to apply advanced genetic engineering methodologies to Cancer Therapy.

ATECT is formed of 3 university partners and 2 small/medium sized enterprise partners; ATECT launched on December 2013 and will run for 5 years. Read more about our partners [our partners].

We will use a combination of technologies including Chimeric Antigen receptors, lentiviral vectors and genome editing tools to generate highly advanced therapeutic cellular products.

Read more [about our technology].


 The research is funded from the European Community's Seventh Framework Programme
2007-2013 FP7-HEALTH-2013-2.4.1-2 under grant agreement #602239
Co-ordinator Martin Pule, University College London, WC1E 6HX, UK